ArticleFrontiers in microbiology2026
Culture supernatants from human-derived commensal bacteria alleviate DNCB-induced atopic dermatitis through modulation of inflammatory and barrier-associated pathways.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isolation and Characterization of a Novel Marine Peptide, WPN-15, from Walleye Pollock (Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by immune dysregulation, impaired epidermal barrier function, and recurrent episodes of itching and inflammation. Emerging evidence suggests that skin-resident microbiota influence host immune responses and may modulate AD pathogenesis. Here, we investigated the anti-inflammatory, barrier-restoring, and neuro-supportive effects of culture supernatants (CSs) derived from skin-resident bacteria. Methods: Human keratinocytes (HaCaT) stimulated with tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) were treated with CSs from various isolates. For in vivo evaluation, a 2,4-dinitrochlorobenzene (DNCB)-induced AD-like mouse model was utilized, receiving topical applications of the CSs. Furthermore, differentiated SH-SY5Y neuronal cells were treated with keratinocyte- or fibroblast-conditioned media, prepared after stimulation with bacterial CSs, to evaluate their neurotrophic potential. Results: CSs from Brachybacterium paraconglomeratum and Brevibacterium casei significantly suppressed interleukin-6 (IL-6) and C-C motif chemokine ligand 17 (CCL17) while restoring filaggrin expression. In keratinocytes and human dermal fibroblasts, these CSs increased brain-derived neurotrophic factor (BDNF) expression. In the DNCB-induced AD-like mouse model, topical application of B. paraconglomeratum and B. casei CSs reduced epidermal hyperplasia and immune cell infiltration, downregulated tyrosine hydroxylase (TH), and restored cutaneous BDNF, glial cell line-derived neurotrophic factor (GDNF), and filaggrin (FLG) expression. In differentiated SH-SY5Y neuronal cells, the conditioned media treatments markedly upregulated BDNF, GDNF, and nerve growth factor (NGF). Mechanistically, CS treatment inhibited p38 MAPK and JAK-STAT signaling. Discussion: Collectively, these findings demonstrate that specific skin-derived bacterial metabolites exert coordinated anti-inflammatory, barrier-reinforcing, and neurotrophic activities, thereby promoting associated changes in neurotrophic markers. Such microbial products may serve as promising biologic candidates for managing atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.